Morgan Stanley is a leading global financial services firm that provides a wide range of services in investment banking, securities, wealth management, and investment management. Catering to a diverse clientele that includes corporations, governments, and individuals, Morgan Stanley offers expert advisory and financing services, helping clients navigate complex financial markets and achieve their financial objectives. The firm is known for its strategic insights, innovative solutions, and commitment to delivering exceptional service, positioning itself as a trusted partner in the world of finance. Read More
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ...
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines.
Speaking at M
Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event.
Chief Executive Officer Mike Raab sa
Morgan Stanley Investment Management (MSIM) announced today that the 1GT private climate equity strategy (1GT) led a €49 million Series E financing round for Amber Electric (Amber or the Company), an energy flexibility platform that enables customers to optimize how they store and use energy at home. This funding will support the Company’s continued growth and expansion in Europe. It follows the recent partnership with E.ON, one of the UK’s largest energy suppliers, which also participated in the latest round.
Cognex (NASDAQ:CGNX) Chief Financial Officer Dennis Fehr said the machine-vision company is pursuing growth across logistics, packaging, semiconductors, electronics and data-center supply chains, supported by artificial intelligence-enabled products, an expanded customer base and operating-efficienc
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
Speaking at t
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform.
Kha
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline.
Speaki
Aurora Innovation (NASDAQ:AUR) is preparing to expand its autonomous-trucking operations through a second-generation hardware rollout, a planned transition toward a driver-as-a-service model and additional manufacturing relationships, Co-founder and CEO Chris Urmson said at the Morgan Stanley Laguna
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Chumi Khurana, senior vice president of U.S. Oncology
WW International (NASDAQ:WW) executives outlined the company’s efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
Speaking at Morgan Stanley’s healthcare conference,
Stanley Black & Decker (NYSE:SWK) CEO Chris Nelson said the company is progressing against three priorities: strengthening its core brands, improving operational execution and accelerating innovation.
Speaking at the Morgan Stanley 14th Annual Laguna Conference, Nelson said the company reported
Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure
IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.
Chief Executive Of
Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care.
Speaking at a Morgan Stanley fireside ch
Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Rockwell Automation (NYSE:ROK) executives said customer sentiment remains broadly positive despite inflation, tariffs and trade-policy uncertainty, with manufacturers continuing to prioritize productivity, modernization and automation investments.
Speaking at Morgan Stanley’s 14th Annual Laguna Con
Cardinal Health (NYSE:CAH) CEO Jason Hollar said the company expects fiscal 2027 to extend the broad operating momentum it generated in fiscal 2026, with all five operating segments positioned for what he described as a “constructive” period.
Speaking at the Morgan Stanley Global Healthcare Confere
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in the
